News

The Board of Directors of Protek OJSC at its meeting, held on May 07, 2013, recommended to the annual general shareholders’ meeting to distribute the profit in the form of payment of dividends in the amount of RUR 2 billion 530 million

OAO Protek announces that on 7 May, 2013 the Board of Directors is going to discuss its suggestion

Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia has announced its preliminary operating results for Q1-2013 according to the management accounts (unaudited).

Protek Group (PRTK:RTS, MICEX), one of the major pharmaceutical companies in Russia operating in all segments of the pharmaceutical market (production, distribution, and retail sales), has announced its financial results for FY-2012.

The management of JSC CV "Protek" hereby reports about the resolution not to send to OJSC "PROTEK" a voluntary offer to acquire ordinary shares of OJSC "PROTEK".

Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia has announced its preliminary operating results for Q4-2012 and 12M 2012 according to the management accounts (unaudited).

Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia, has announced its preliminary operating results for Q3-2012 and 9M 2012 according to the management accounts (unaudited).

Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia operating in all segments of the pharmaceutical market (production, distribution, and retail sales), announces its financial results for 1HY-2012.

Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia, announces its preliminary operating results for Q2-2012 and 1H-2012 based on unaudited management accounts..

The Sotex company (a production business segment of Protek Group) started promotion of Exportal (international non-proprietary name: lactitol) under the contract with the developer and manufacturer of the drug product, a Russian company Pharmvilar FPK.